Drug intelligence / Profile preview

RCC-33

Development stage: Preclinical
Lead developer: CNBX Pharmaceuticals
Modality: Small Molecules
Administration: Intraperitoneal, Oral

Overview

**RCC-33** is Cannabics Pharmaceuticals' proprietary, non-psychoactive cannabinoid-based antitumor formulation being developed for **colorectal cancer**. Its individual active constituents, direct molecular targets, and precise mechanism of action have not been publicly disclosed. Cannabics has reported antitumor activity in preclinical colorectal-cancer models, including tumor-growth inhibition and prolonged survival in mice, and has described plans for FDA pre-IND activities and eventual Phase I/IIa clinical development. ([cnbxpharma.com](https://cnbxpharma.com/))

Other names: Cannabics RCC-33

Beyond the preview

Go deeper on RCC-33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCC-33.

Explore the full profile